Fuxing Zhao

Dr. Fuxing Zhao


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2023 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
ZZZijun Zhu
Zijun Zhu
GSGuoshuang Shen
Guoshuang Shen
JLJinming Li
Jinming Li
TQTianlei Qiu
Tianlei Qiu
QFQianqian Fang
Qianqian Fang
JZJiuda Zhao
Jiuda Zhao

23 November 2021 in BMC Cancer
Verified
Journal Article
Open access
PDF file
YXYuanfang Xin
Yuanfang Xin
GSGuoshuang Shen
Guoshuang Shen
Yong-Hui ZhengYong-Hui Zheng
Yong-Hui Zheng
YGYumei Guan
Yumei Guan
XHXingfa Huo
Xingfa Huo
JZJiuda Zhao
Jiuda Zhao
Purpose: Some studies have shown that Immune checkpoint inhibitors (ICIs) have a favorable efficacy in advanced triple negative breast cancer (TNBC) patients, but the results are controversial in neoadjuvant chemotherapy (NACT) stage. The purpose of this study is to evaluate the efficacy and safety after NACT plus ICIs in early TNBC patients. Methods: After searching PubMed, EMBASE, the Cochrane library and several mainly oncology conferences up to 30 January 2021 systematically, and define randomized controlled trials (RCTs) exploring the efficacy and safety of programmed death protein-1/programmed cell death-Ligand 1(PD-1/PD-L1) inhibitors plus neoadjuvant chemotherapy in TNBC patients. The primary endpoint was the pathological complete response (pCR) in intention-to-treat populations (ITT), and the secondary endpoints were event-free survival (EFS) and safety analysis in the ITT populations. Results: Six RCTs (N = 2142) were included in our meta-analysis; NACT plus ICIs increased pCR rates compared with NACT in intention-to-treat (ITT) populations (OR: 1.91; 95% CI: 1.32–2.78, P < 0.001). The pCR rate also increased in both PD-L1 positive (OR: 1.65; 95% CI: 1.26–2.16, P < 0.001) and PD-L1 negative patients (OR: 1.56; 95% CI: 1.04–2.33, P = 0.03), especially in PD-L1 positive patients. The benefit was also observed in nodal-positive populations (OR: 2.52; 95% CI: 1.69–3.77, P < 0.001) and Eastern Cooperative Oncology Group performance-status score (ECOG PS) 0 subgroup (OR: 1.90; 95% CI: 1.42–2.53, P < 0.001). Three RCTs (N = 1615) reported EFS and the results showed that adding PD-1/PD-L1 inhibitors increased EFS (HR 0.65, 95% CI 0.50–0.83, P = 0.0007) in ITT populations with a short follow-up time. In the safety analysis of 2205 patients with early TNBC from five eligible studies, NACT plus ICIs had a higher risk of grade 3–4 diarrhea (OR: 2.54; 95% CI: 1.21–5.32; P = 0.01), any grade of adverse effects(AEs)including vomiting (OR: 1.37; 95% CI: 1.00–1.86; P = 0.05), hyperthyroidism (OR: 6.04; 95% CI: 2.39–15.29; P < 0.001), and hypothyroidism (OR: 5.04; 95% CI: 3.02–8.39; P < 0.001). Conclusions: PD-1/PD-L1 inhibitors combined with chemotherapy can improve pCR rates and EFS, and with an increased incidence of some immune-related AEs compared with chemotherapy alone. NACT plus ICIs might be an option in patients with in PD-L1 positive and high-risk populations with positive nodal disease early TNBC.

22 September 2022 in Clinical and Experimental Medicine
Verified
Journal Article
Closed access
PDF file
YLYaobang Liu
Yaobang Liu
XHXingfa Huo
Xingfa Huo
QLQi Li
Qi Li
YLYishuang Li
Yishuang Li
GSGuoshuang Shen
Guoshuang Shen
XLXin-lan Liu
Xin-lan Liu

1 December 2021 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
XHXingfa Huo
Xingfa Huo
GSGuoshuang Shen
Guoshuang Shen
ZLZhen Liu
Zhen Liu
YLYuhua Liang
Yuhua Liang
JLJinming Li
Jinming Li
JZJiuda Zhao
Jiuda Zhao


30 April 2023 in Clinical and Experimental Medicine
Verified
Journal Article
Closed access
PDF file
YZYonghui Zheng
Yonghui Zheng
GSGuoshuang Shen
Guoshuang Shen
CZChengrong Zhang
Chengrong Zhang
XHXingfa Huo
Xingfa Huo
YXYuanfang Xin
Yuanfang Xin
JZJiuda Zhao
Jiuda Zhao